Completed PHASE2 INTERVENTIONAL 1-arm NCT02807883

Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia

Sponsor: Amgen

Interventions Blinatumomab Hematopoietic Cell Transplantation

Updated 12 times since 2017 Last updated: Dec 30, 2022 Started: Aug 31, 2016 Primary completion: Feb 1, 2022 Completion: Feb 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Lymphoblastic Leukemia and is currently completed. Amgen leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2023 — Jul 2024 [monthly]

Completed PHASE2
Mar 2022 — Feb 2023 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE2

▶ Show 7 earlier versions

Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2019 — Dec 2020 [monthly]

Recruiting PHASE2
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Jun 2019 [monthly]

Recruiting PHASE2
Mar 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States